Company Profile
Ocugen Stock Price, News & Catalysts
- Ticker:
- OCGN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.04 USD (0.00%)
Close
Last updated: October 6, 2026
454M USD
Market cap
Why the stock is moving
The latest monitored headline was “Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate”. OCGN was little changed in the corresponding trading session, closing at $1.04 on Oct 6, 2026.
Company overview
Gene Therapies for Retinal Disease
Ocugen develops one-time gene therapies for inherited and acquired causes of blindness. Its lead ophthalmology programs are designed to address broad patient populations rather than only individuals with a single disease-causing mutation.
Modifier Gene Therapy Platform
The platform delivers master regulatory genes that influence multiple biological pathways involved in retinal health. This gene-agnostic strategy is intended to restore or preserve retinal function across patients with different mutations and in multifactorial diseases.
OCU400 for Retinitis Pigmentosa
OCU400 is a modifier gene therapy in the pivotal Phase 3 liMeliGhT trial for retinitis pigmentosa. The study includes patients with multiple genetic mutations and is intended to support a broad treatment label.
OCU410ST for Stargardt Disease
OCU410ST is being evaluated in the pivotal Phase 2/3 GARDian3 study for Stargardt disease. The program is designed as a mutation-agnostic treatment for a condition with no approved therapy.
OCU410 for Geographic Atrophy
OCU410 is being developed for geographic atrophy secondary to dry age-related macular degeneration. Phase 2 results supported advancement into a combined global Phase 3 registrational study.
One-Time Administration and Regional Partnerships
The retinal programs are delivered through subretinal administration with the objective of durable benefit from a single treatment. Ocugen is pursuing regional licensing partnerships while retaining rights in major markets.
Future catalysts
- Initiation of the OCU410 Phase 3 ArMaDa3 trial in geographic atrophy in the third quarter of 2026.
- Topline Phase 3 results from liMeliGhT for OCU400 in retinitis pigmentosa in the first quarter of 2027.
- Topline Phase 2/3 results from GARDian3 for OCU410ST in Stargardt disease in the second quarter of 2027.
- BLA submission for OCU410ST in mid-2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ocugen (OCGN)?
Ocugen (OCGN) most recently closed at 1.04 USD, a 0.00% move versus the previous session.
What is the market cap of Ocugen (OCGN)?
Ocugen currently has a market capitalization of 454M USD on BioPharmSignal.
What does Ocugen do?
Gene Therapies for Retinal Disease Ocugen develops one-time gene therapies for inherited and acquired causes of blindness. Its lead ophthalmology programs are designed to address broad patient populations rather than only individuals with a single disease-causing mutation. Modifier Gene Therapy Platform The platform delivers master regulatory genes that...
On which exchange is OCGN stock listed?
Ocugen (OCGN) is associated with NASDAQ, United States, Biopharma.
What is Gene?
Gene Therapies for Retinal Disease Ocugen develops one-time gene therapies for inherited and acquired causes of blindness.
Which conditions is Ocugen targeting with Gene?
Ocugen is associated with ophthalmology, genetic disease based on its company overview and current catalyst commentary.
How does Ocugen describe recent progress with Gene?
Initiation of the OCU410 Phase 3 ArMaDa3 trial in geographic atrophy in the third quarter of 2026. Topline Phase 3 results from liMeliGhT for OCU400 in retinitis pigmentosa in the first quarter of 2027. Topline Phase 2/3 results from GARDian3 for OCU410ST in Stargardt disease in the second quarter of 2027. BLA submission for OCU410ST in mid-2027.
What is Therapies?
Gene Therapies for Retinal Disease Ocugen develops one-time gene therapies for inherited and acquired causes of blindness.